malformation

(redirected from cavernous malformation)
Also found in: Dictionary, Thesaurus, Medical, Legal.

malformation

Pathol a deformity in the shape or structure of a part, esp when congenital

malformation

[‚mal·fər′mā·shən]
(medicine)
A deformity of a part of the body resulting from abnormal development.
References in periodicals archive ?
Cerebral cavernous malformations and pregnancy: Hemorrhage risk and influence on obstetrical management.
Symptoms can also be related to the coexistence with other vascular malformations, primarily cavernous malformations (CMs).
Cavernous malformations are composed of well-circumscribed vascular spaces containing blood in various stages of evolution.
Intramedullary spinal cavernous malformation following spinal irradiation.
Objective: To explore the factors associated with preoperative and postoperative epileptic seizure in patients with cavernous malformations (CMs).
Cavernous malformation (CM), also known as cavernous angioma, cavernous hemangioma or cavernoma, is a highly vascular lesion that can be found anywhere in the body.
Successful brainstem cavernous malformation resection after repeated hemorrhages during pregnancy.
In some cases, the cavernous malformation may lead to significant bleeding or hemorrhage into the brain tissue, causing weakness, numbness, difficulty in speaking, difficulty in seeing, gait unsteadiness or incoordination.
director of the Molecular Medicine Program and corresponding author of a study statins can offer a safe, inexpensive treatment for cerebral cavernous malformation (CCM), a disorder with no known drug therapy.
The cause of the recurrent SAH is determined on imaging in only 50% of cases (3) and includes dural pathology, postsurgical CSF cavity with neovascularity, bleeding central nervous system (CNS) tumours (ependymoma, oligodendroglioma and astrocytoma), vascular malformations (arteriovenous malformations and cavernous malformation near the brain's surface), aneurysms, and in the spinal cord--tumours, arteriovenous malformations and traumatic nerve root avulsion.
BA-1049 is a first-in-class Rho kinase 2 (ROCK2) inhibitor targeting the protein kinase that causes cerebral cavernous malformation.